Table 2.

Immunological Response to 2 Doses of H7N3 BC 2004/AA ca vaccine

		Reciprocal mean ± SD log 2 antibody
		HI using 4 HAU and horse RBC			HI using 2 HAU and horse RBC			Serum Neut Ab Response			Serum HA-IgG ELISAa			Serum HA-IgA ELISAa			Nasal Wash HA-IgA ELISAa
Dose	Number of vaccinees	Pre	Postb	% with 34-fold rise	Pre	Post	% with 34-fold rise	Pre	Post	% with 34-fold rise	Pre	Post	% with 34-fold rise	Pre	Post	% with 34-fold rise	Pre	Post	% with 34-fold rise
First Dose	21c	1.0 ± 0.0	1.3 ± 0.8	10	1.1 ± 0.4	1.9 ± 1.3	14	2.5 ± 0.4	3.0 ± 0.8	10	6.7 ± 1.6	7.3(1.6)	29	7.6 ± 2.1	8.8 ± 1.9	52	6.9 ± 1.7	7.8 ± 1.5	24
Second Dose	17	1.3 ± 0.8	2.2 ± 1.5	29	1.9 ± 1.3	3.0 ± 1.3	41	3.0 ± 0.9	4.0 ± 1.8	41	6.9 ± 1.4	7.6(1.4)	24	8.4 ± 1.4	9.0 ± 1.5	29	7.7 ± 1.4	8.2 ± 2.3	12
Any dose	21	1.0 ± 0.0	2.2 ± 1.4	43d	1.1 ± 0.4	3.0 ± 1.2	62e,f	2.5 ± 0.4	4.0 ± 1.7	48d	6.7 ± 1.6	7.7(1.5)	48e	7.6 ± 2.1	9.2 ± 1.9	71	6.9 ± 1.7	8.2 ± 2.1	33g

Abbreviations used are as follows: SD= standard deviation, HI= hemagglutinin Inhibition assay, RBC=r ed blood cell, Neut= neutralizing, Ab= antibody, HA= hemagglutinin, HAU=hemagglutinin units, ELISA= Enzyme Linked Immunosorbent Assay, No.= Number.

^aELISA performed utilizing recombinant H7 HA protein from a heterologous A/Netherlands/219/03 (H7N7) virus expressed in a baculovirus vector.

^bPost values drawn on day 28 for dose 1, day 27 for dose 2.

^cOnly 20 subjects had results available after dose 1; 1 subject did not return for the day 28 visit.

^d2 individuals (11%) who did not receive dose 2 were found to have a >4 fold rise in titers at day 61.

^e1 person (5%) who did not have blood drawn at day 28 and who did not receive dose 2 was found to have a 4 fold rise in titers on day 61.

^f2 individuals had a gradual rise in titer between dose 1 and dose 2.

^g1 individual had a gradual rise in titer between dose 1 and dose 2.